Kusajili – Clinical trials directory

Result of your search per sponsor: Aline Guillot, MD

Woman and Man Max 99 years
Aline Guillot, MD Update Il y a 4 ans

Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma The purpose of this study was to evaluate the safety and efficacy of CAP-232 in the treatment of patients with previously treated (refractory) renal cell carcinoma

Country France
organs None
Specialty None

Closed trial

More information